Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | DPP4 | P27487 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | PTGFR | P43088 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17590311 | 1.00 | TSHR (0.50) | TSHRFFAR1TDP1L3MBTL1DPP4 | |
| SCHEMBL13870218 | 0.89 | LTB4R (0.48) | FFAR1TDP1L3MBTL1ALDH1A1HPGD | |
| SCHEMBL9511889 | 0.86 | TSHR (0.47) | TSHRFFAR1TDP1L3MBTL1DPP4 | |
| SCHEMBL27500484 | 0.85 | OPRK1 (0.50) | TSHRDPP4CYP1A2 | |
| SCHEMBL16080190 | 0.85 | OPRK1 (0.50) | TSHRDPP4CYP1A2 | |
| SCHEMBL1073143 | 0.84 | TSHR (0.68) | TSHRALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL473576 | 0.84 | TSHR (0.68) | TSHRALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL12670558 | 0.84 | TSHR (0.68) | TSHRALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL264775 | 0.84 | TSHR (0.68) | TSHRALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL2692838 | 0.83 | TSHR (0.49) | TSHRCYP1A2GABRR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4709710-A1 | IONIZABLE CATIONIC LIPIDS FOR RNA DELIVERY | Arcturus Therapeutics, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| US-20240391870-A1 | IONIZABLE CATIONIC LIPIDS FOR RNA DELIVERY | ARCTURUS THERAPEUTICS, INC. | 2024-11-28 | — | — | US | disclosed |
| WO-2024233750-A1 | IONIZABLE CATIONIC LIPIDS FOR RNA DELIVERY | ARCTURUS THERAPEUTICS, INC. (US) | 2024-11-14 | — | — | WO | disclosed |
| EP-4430026-A1 | IONIZABLE CATIONIC LIPIDS FOR RNA DELIVERY | Arcturus Therapeutics, Inc. (US) | 2024-09-18 | — | — | EP | disclosed |
| CN-118451059-A | Ionizable cationic lipids for RNA delivery | 阿克丘勒斯治疗公司 | 2024-08-06 | — | — | CN | disclosed |
| WO-2024148312-A1 | COMPOSITIONS, SYSTEMS, AND METHODS FOR AMINO ACID SYNTHESIS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-07-11 | — | — | WO | disclosed |
| US-20230295081-A1 | IONIZABLE CATIONIC LIPIDS FOR RNA DELIVERY | ARCTURUS THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230295081-A1 | IONIZABLE CATIONIC LIPIDS FOR RNA DELIVERY | ARCTURUS THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230295081-A1 | IONIZABLE CATIONIC LIPIDS FOR RNA DELIVERY | ARCTURUS THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| WO-2023086514-A1 | IONIZABLE CATIONIC LIPIDS FOR RNA DELIVERY | ARCTURUS THERAPEUTICS, INC. (US) | 2023-05-19 | — | — | WO | disclosed |
| WO-2023086514-A1 | IONIZABLE CATIONIC LIPIDS FOR RNA DELIVERY | ARCTURUS THERAPEUTICS, INC. (US) | 2023-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240391870-A1 | IONIZABLE CATIONIC LIPIDS FOR RNA DELIVERY | NSUN3, POLRMT, NPC1L1 | TSHR 1676/4885FFAR1 1510/4885TDP1 2944/4885 |
| US-20230295081-A1 | IONIZABLE CATIONIC LIPIDS FOR RNA DELIVERY | NSUN3, POLRMT, NPC1L1 | TSHR 1676/4885FFAR1 1510/4885TDP1 2944/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.